In a groundbreaking study poised to significantly advance the fight against aggressive prostate cancer, researchers at Columbia University Irving Medical Center have identified the gene Sirtuin 1 (Sirt1) as a crucial driver in the development of neuroendocrine prostate cancer (NEPC). NEPC represents a particularly lethal form of prostate cancer that often emerges following resistance to conventional treatments. Published in the prestigious Journal of Experimental Medicine, this study illuminates the genetic and molecular mechanisms underpinning NEPC and offers a promising new therapeutic target for what has long been considered an intractable disease.
Prostate cancer affects one in six men in their lifetime, making it one of the most prevalent cancers worldwide. The frontline treatment for prostate cancer is androgen deprivation therapy (ADT), a hormone-based approach aimed at halting tumor progression by cutting off androgen signaling. Yet, despite initial efficacy, ADT frequently loses effectiveness as tumors adapt, giving rise to a more aggressive and treatment-resistant tumor subtype known as neuroendocrine prostate cancer. This transformation, driven by cellular plasticity and lineage reprogramming, has posed a significant challenge to researchers and oncologists seeking durable treatment outcomes.
The phenomenon of lineage plasticity, whereby prostate adenocarcinoma cells undergo transdifferentiation into neuroendocrine-like cells under the selective pressure of ADT, lies at the heart of NEPC progression. Until now, the underlying molecular players orchestrating this transformation were largely unknown. By elucidating the genetic landscape of this progression, the Columbia team aimed to identify novel key drivers enabling tumor adaptability and resistance.
Using a sophisticated forward genetic screen approach in mice, the investigators screened for recurrent mutations across independent prostate tumors that promote the NEPC phenotype. This high-throughput genomic survey revealed 75 candidate genes potentially implicated in driving neuroendocrine features. Among these, Sirtuin 1 emerged as the most compelling and consistent positive regulator. Sirt1 encodes an NAD+-dependent deacetylase enzyme involved in a broad array of cellular functions, including epigenetic regulation, metabolism, DNA repair, and stress responses.
Sirt1’s role in cancer has been contentious, displaying context-dependent activities that can promote or suppress tumor growth depending on the cancer type and cellular environment. However, this new study provides convincing evidence positioning Sirt1 as a potent promoter of NEPC specifically. To validate this, the researchers employed human prostate cancer cell lines characterized by varying levels of SIRT1 expression. Inducing NEPC differentiation in these cells led to increased activation of SIRT1 target genes coupled with suppression of genes usually inhibited by SIRT1, reinforcing the enzyme’s central role in neuroendocrine lineage determination.
Further experiments showed that pharmacologically activating SIRT1 in prostate cancer cells that naturally express it at low levels provoked a robust upregulation of neuroendocrine markers, effectively mirroring the aggressive tumor phenotype. Conversely, silencing Sirt1 expression profoundly curtailed tumor growth in NEPC mouse models. This finding underscores the enzyme’s potential as a therapeutic vulnerability, as its inhibition disrupts the plasticity and dedifferentiation processes essential for tumor aggressiveness.
Perhaps most promisingly, the team evaluated the effects of Selisistat, an FDA-approved SIRT1 inhibitor originally developed for treating Huntington’s disease, on NEPC tumors in vivo. Treatment with Selisistat not only suppressed tumor progression but also notably reversed the neuroendocrine phenotype, indicating that pharmacological disruption of SIRT1 activity could restore tumor sensitivity and undermine lethal cancer progression. This repurposing of Selisistat represents a practical and accelerated pathway toward clinical application.
According to Dr. Cory Abate-Shen, professor at Columbia University Vagelos College of Physicians and Surgeons and co-leader of this research, “Our findings demonstrate that SIRT1 plays a pivotal role in promoting neuroendocrine prostate cancer. This extends beyond general tumor growth regulation to encompass lineage plasticity and cellular identity reprogramming.” This breakthrough highlights SIRT1 as an attractive and clinically actionable target deserving of expedited investigation in future clinical studies.
Complementing this therapeutic insight, the study also elucidates important mechanistic pathways regulated by SIRT1 in NEPC cells. The enzyme’s enzymatic activity influences gene expression patterns that modulate chromatin accessibility and metabolic reprogramming—two fundamental processes implicated in enabling tumor cells to escape differentiation constraints and develop therapy-resistant phenotypes. This dual-level regulation may explain the difficulty encountered in controlling NEPC progression using conventional therapies.
Moreover, by integrating genetic, molecular, and pharmacological data, the research establishes a comprehensive model in which SIRT1 activation masterfully orchestrates the complex network of transcriptional programs necessary for neuroendocrine differentiation. This gene regulatory influence is tightly linked to metabolic adaptations that support tumor survival under androgen-deprived conditions.
The implications of this research are vast, as it paves the way for the development of novel combination therapies that inhibit both androgen receptor signaling and SIRT1 function. Such strategies could effectively thwart the emergence of neuroendocrine prostate cancer at its root, improving patient outcomes and survival rates. Given the current lack of effective treatments for NEPC, these findings may mark a turning point in precision oncology for prostate cancer patients worldwide.
Columbia’s innovative approach, combining forward genetic screening with translational pharmacology, exemplifies the power of integrating genetic discovery with drug repurposing to accelerate clinical impact. While further preclinical validation and clinical trials are warranted, this study positions SIRT1 inhibition as a beacon of hope for tackling the current therapeutic impasse in lethal prostate cancer variants.
As research unfolds, the scientific and clinical communities will closely monitor the progression of SIRT1-targeted therapies through development pipelines. Should these findings be replicated in human clinical contexts, the prospect of significantly extending patient survival and quality of life becomes tangible. This work not only expands our understanding of the molecular underpinnings of cancer plasticity but also sets a blueprint for addressing other malignancies governed by similar mechanisms.
In summary, this landmark study by Nunes de Almeida and colleagues, published on May 28, 2026, in the Journal of Experimental Medicine, identifies Sirtuin 1 as a fundamental genetic driver of neuroendocrine prostate cancer and highlights the therapeutic promise of SIRT1 inhibitors like Selisistat in reversing this aggressive disease phenotype. By revealing the molecular intricacies of lineage plasticity and drug resistance, it invigorates the quest for effective treatments against one of the deadliest forms of prostate cancer.
Subject of Research: Animals
Article Title: A forward genetic screen identifies Sirtuin1 as a driver of neuroendocrine prostate cancer
News Publication Date: 28-May-2026
Web References: http://dx.doi.org/10.1084/jem.20241484
References: Nunes de Almeida et al. 2026. Journal of Experimental Medicine
Image Credits: © 2026 Nunes de Almeida et al. Originally published in Journal of Experimental Medicine
Keywords: Prostate cancer, Neuroendocrine prostate cancer, Sirtuin 1, NEPC, Lineage plasticity, Androgen deprivation therapy resistance, SIRT1 inhibitor, Selisistat, Tumor biology, Gene regulation
